Appeals & Response Plans
- Tropical Cyclone Sagar - May 2018
- Ethiopia: Floods and Landslides - Apr 2018
- Ethiopia: Floods - Aug 2017
- Ethiopia: Measles Outbreak - May 2017
- East Africa: Armyworm Infestation - Mar 2017
- Ethiopia: Acute Watery Diarrhoea (AWD) Outbreak - May 2016
- Ethiopia: Floods - Apr 2016
- Ethiopia: Floods - Oct 2015
- Ethiopia: Drought - 2015-2018
- Ethiopia: Floods - Oct 2014
Most read reports
- The Crisis Below the Headlines: Conflict Displacement in Ethiopia
- Displacement Tracking Matrix (DTM) Ethiopia - Round 13: September - October 2018
- Eritrea-Ethiopia peace leads to a refugee surge
- Ethiopia Food Security Outlook, October 2018 to May 2019
For Immediate Release
Monday, August 20, 2018 Office of Press Relations
Telephone: +1.202.712.4320 | Email: firstname.lastname@example.org
Center for Strategic and International Studies
August 20, 2018
ADMINISTRATOR GREEN: Good morning, everyone. Thank you, Dan, for that kind introduction and thanks to all of you for being here to help mark this very important occasion.
Les 27 pays cibles en Afrique subsaharienne et la sous-région du Grand Mékong on bénéficié de plus de $5,4+ milliards de ressources pour la prévention, le traitement et la lutte contre le paludisme.
Despite remarkable progress in recent years, malaria remains a leading cause of sickness and death across much of sub-Saharan Africa. Malaria disproportionately impacts the rural poor, typically people who must walk for miles to seek treatment. It is also a leading cause of absenteeism among employees, increased health care spending, decreased productivity, and approximately 50 percent of all preventable school absences in Africa. Malaria helps to trap families in a vicious cycle of disease and poverty.
A variety of natural hazards—including cyclical drought, floods, and environmental degradation—are endemic to the East and Central Africa (ECA) region, where conflict, rapid population growth, and limited government response capacity have compounded humanitarian needs over the last decade. Between FY 2008 and FY 2017, USAID’s Office of U.S.
Modeling Outputs Can Be Valuable When Uncertainty Is Appropriately Acknowledged, but Misleading When Not
Extended Effectiveness of the Etonogestrel-Releasing Contraceptive Implant and the 20 µg Levonorgestrel-Releasing Intrauterine System for 2 Years Beyond U.S. Food and Drug Administration Product Labeling
Interventions for Preventing Unintended, Rapid Repeat Pregnancy Among Adolescents: A Review of the Evidence and Lessons From High-Quality Evaluations